Compare DCBO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | PRTA |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.9M | 539.9M |
| IPO Year | 2020 | 2013 |
| Metric | DCBO | PRTA |
|---|---|---|
| Price | $16.20 | $10.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $32.00 | $19.00 |
| AVG Volume (30 Days) | 100.0K | ★ 449.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | $12.89 | $1,111.38 |
| Revenue Next Year | $11.44 | N/A |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.39 | $4.32 |
| 52 Week High | $33.69 | $11.69 |
| Indicator | DCBO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 67.15 |
| Support Level | N/A | $9.69 |
| Resistance Level | $20.15 | $10.90 |
| Average True Range (ATR) | 0.84 | 0.40 |
| MACD | -0.17 | 0.10 |
| Stochastic Oscillator | 42.96 | 96.87 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.